OFFICIAL PUBLICATION OF

by its subsidiary APPco

Apotex decision a warning bell

Megan Haggan 14/04/2016

Apotex’ decision to pull two of its PBS-listed products should ring an alarm for the health and pharmaceuticals sector, says Belinda Wood, CEO of the Generic and Biosimilar Medicines Association. Yesterday Apotex announced that it will be ceasing supply of two PBS listed prescription products from its portfolio: paracetamol/codeine tablets 500mg/30mg blister pack 20; and

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Funding secured for non-8CPA programs

Medschecks and Diabetes MedsCheck are included and funded under the 8CPA. The programs under the 8CPA will be undergoing a…

Anthony Tassone

Eli Lilly clarifies Mounjaro availability

One would think they could have made a commercial decision eith a needle maker to supply requisite number of needles…

Erin Threlfall

Funding secured for non-8CPA programs

This is a big step forward in securing the sustainability and viability of HMRs and RMMRs. Remember there is an…

Debbie Rigby

Funding secured for non-8CPA programs

So well done to the PSA for securing this funding. So important that these very valuable program finally gets looked…

Bente Hart

Apotex decision a warning bell

Previous Queensland pharmacist vaccination now permanent

Next Aussies encouraged to vaccinate and help kids in India

Shingles: managing a distressing skin condition

Impetigo: cause and treatment

Topical retinoids: versatile skin care ingredients

Ceramides: what are they and why are they important?

MENU

Previous Queensland pharmacist vaccination now permanent

Next Aussies encouraged to vaccinate and help kids in India

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.